This study investigates the influence of sexual counseling using the PLISSIT model on various aspects of patients undergoing hip replacement. The PLISSIT model is employed to guide the counseling process. The research aims to assess how this counseling intervention affects sexual function, quality of life, and overall comfort for these patients. By addressing these factors, the study seeks to shed light on potential improvements in the well-being and experiences of individuals who have undergone hip replacement surgery.

Start Date01 Nov 2024

Sponsor / Collaborator

Medeniyet University

[+1]

NCT06635395

/ Not yet recruitingNot ApplicableIIT

Translation and Cross-Cultural Adaptation of the Baltimore Orthopedic Subscapularis Score Into Turkish

The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society and to make its validity and reliability in Turkish. The BOSS was developed by Hameker et al to differentiate subscapularis tears from other rotator cuff muscle tears in patients with rotator cuff injuries. The BOSS has 5 questions. This study will be conducted with patients with rotator cuff injuries. The patients will be sought to answer questionnaires during regular rehabilitation sessions. 25 participants will be included in the study. In order to evaluate the validity of the BOSS, the Western Ontario Rotator Cuff Disability Index (WORC), which can evaluate the functionality of the shoulder in patients with rotator cuff injury and has been validated in Turkish, and the SF-12 which can evaluate the quality of life and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.

Start Date01 Nov 2024

Sponsor / Collaborator

Medeniyet University

NCT06630039

/ Not yet recruitingNot ApplicableIIT

Examination of the Validity and Reliability of the Short-Western Ontario Rotator Cuff Disability Index in Turkish in Patients With Rotator Cuff Injury

The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society and to make its validity and reliability in Turkish. The Western Ontario Rotator Cuff Disability Index (WORC) developed by Kirkley et al assesses quality of life in patients with Rotator Cuff İnjury. The WORC has 21 questions. The WORC was shortened and renamed as Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC). The SHORTWORC consists of 7 questions. This study will be conducted with patients with rotator cuff injuries. The patients will be sought to answer questionnaires during regular rehabilitation sessions. 35 participants will be included in the study. In order to evaluate the validity of the SHORTWORC, the Western Ontario Rotator Cuff Disability Index (WORC), which can evaluate the quality of life in patients with rotator cuff injury and has been validated in Turkish, and the The University of California-Los Angeles (UCLA) shoulder scale, which can evaluate the functionality of shoulder and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.

Start Date20 Oct 2024

Sponsor / Collaborator

Medeniyet University

100 Clinical Results associated with Medeniyet University

0 Patents (Medical) associated with Medeniyet University

1,927

Literatures (Medical) associated with Medeniyet University

01 Mar 2025·Burns

Does prolotherapy have an effect on the care of pressure injuries? A pilot study

Article

Author: Koçoğlu, Hasan ; Eroğlu, Hatice Eda ; Eroğlu, Nermin ; Kökkız, Rukiye

BACKGROUNDThis study contributes to wound healing with prolotherapy in people with pressure injuries. The study was planned and conducted as a randomized controlled trial to determine the effect of prolotherapy on the care of pressure injuries.METHODSThe study was carried out with patients with pressure injuries in the intensive care unit of a city hospital between April and June 2023. A power analysis was performed, and the sample size was calculated as 20 patients, including 10 in the intervention and 10 in the control group. The patients in the experimental group were given wound care with gelofusine as prolotherapy in the morning and evening for three days, and the injury site was covered with a sterile sponge and fixation tape. The patients in the control group were treated with saline in the morning and evening for three days. In both groups, the wound width, depth, and length were measured and evaluated prior to each intervention for three days.RESULTSIn the study, a significant difference was found between the mean ages of the participants in the experimental and control groups (p < 0.05). The decrease in width measurements in the experimental group was found to be statistically significant compared to the previous measurements, while the increase in width measurements in the control group was significant compared to the previous measurements (p < 0.05). Depth measurements decreased statistically significantly in the experimental group, while they increased significantly in the control group compared to previous measurement values (p < 0.05).CONCLUSIONIn conclusion, it was determined that the administration of gelofusine for pressure injuries as prolotherapy in the experimental group may be more effective in wound healing than saline treatment applied in the control group. Further studies are warranted.

02 Jan 2025·Applied Neuropsychology: Child

Executive functions in adolescents with gender dysphoria

Article

Author: Yazkan Akgül, Gözde ; Yıldırım Budak, Burcu ; Perdahlı Fiş, Neşe ; Erdoğdu Yıldırım, Ayşe Burcu

Aim: Aim of this study is evaluating EF by performing neurocognitive tests, and to identify gender-related differences in EF between adolescents with and without GD.Methods: 8 Female-to-Male transgender adolescents (FtMs), and 14 Male-to-Female transsexual adolescents (MtFs) (Gender Dysphoria Group, GDG) and 29 boys, 21 girls (Control Group, CG), were tested in a cross-sectional study, using the Wisconsin Card Sorting Test (WCST), Controlled Oral Word Association Test (COWAT), and Stroop Color and Word Test (SCWT). The psychiatric diagnoses were established by using the KD-SADS.Results: Among GDG 72.7%, had at least one psychopathology. There weren't any significant differences in, estimated IQ scores, or WCST subtest scores between the 2 groups. COWAT total word count and SCWT-5 total duration test scores were better in the CG.Conclusion: CG had better performance on verbal fluency and response inhibition whereas no differences found on set shifting abilities. In consideration of the existence of EF-related impairment in adolescents with GD, appropriate support and interventions are expected to improve their adaptation skills and comorbid psychopathologies. These results should be interprete cautiously and additional larger scale studies are needed to obtain more comprehensive data related to gender differences in EF of adolescents with GD.

01 Jan 2025·Respiratory Medicine

Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry

Article

Author: Donmez, Halil ; Yildiz, Fusun ; Karadogan, Dilek ; Ucar, Elif Yilmazel ; Basyigit, Ilknur ; Gemicioglu, Bilun ; Kalpaklioglu, Ayse Fusun ; Kaya, Saltuk Bugra ; Arslan, Bahar ; Sekibag, Yonca ; Ozdemir, Secil Kepil ; Gokmen, Derya ; Cengiz, Ali ; Seker, Ummuhan ; Aslan, Ayse Feyza ; Karakis, Gulden Pasaoglu ; Ozgur, Eylem Sercan ; Nayci, Sibel ; Goksel, Ozlem ; Havlucu, Yavuz ; Yavuz, Yasemin ; Aykac, Enes Furkan ; Keren, Metin ; Ozturk, Ayse Bilge ; Ozden, Seyma ; Polatli, Mehmet ; Yilmaz, Insu ; Cetin, Gulden Pacaci ; Buhari, Gozde Koycu ; Dirol, Hulya ; Demir, Semra ; Ozgun Niksarlioglu, Elif Yelda ; Cakmak, Mehmet Erdem ; Baris, Serap Argun ; Kalkan, Ilkay Koca ; Unal, Derya ; Kavas, Murat ; Gumusburun, Reyhan ; Abadoglu, Oznur ; Ogus, Aliye Candan ; Yorgancioglu, Arzu ; Isik, Sacide Rana ; Çelik, Gülfem Elif ; Akten, Hatice Serpil ; Simsek, Gokcen Omeroglu ; Yorulmaz, Irfan ; Bogatekin, Gulhan ; Beyaz, Sengul ; Turk, Murat ; Ediger, Dane ; Bozkurt, Nurgul ; Erbay, Muge ; Sozener, Zeynep Celebi ; Yucel, Taskin ; Yalim, Sumeyra Alan ; Tatar, Emel Cadalli ; Dursun, Adile Berna ; Damadoglu, Ebru ; Karakaya, Gul ; Pekbak, Gulseren ; Ozer, Serdar ; Alpagat, Gulistan ; Mungan, Dilsad ; Dursun, Engin ; Uysal, Mehmet Atilla ; Yulug, Demet Polat ; Pur, Leyla ; Gul, Ozcan ; Baccioglu, Ayse ; Cerci, Pamir ; Tezcaner, Zahide Ciler ; Gelincik, Asli ; Erkekol, Ferda Oner ; Can, Ali ; Erdinc, Munevver ; Gulen, Sule Tas ; Sevinc, Can ; Aydin, Omur ; Akkurt, Bulent ; Gunaydin, Fatma Esra ; Oguzulgen, Ipek Kivilcim ; Tepetam, Fatma Merve ; Bulut, Ismet ; Kara, Bilge Yilmaz ; Suslu, Ahmet Emre ; Erdogan, Tuba ; Orcen, Cihan ; Katran, Zeynep Yegin ; Yakut, Tugce ; Inan, Sinem ; Karaoglanoglu, Selen ; Soyyigit, Sadan ; Kendirlinan, Resat ; Kalyoncu, Ali Fuat ; Kizilirmak, Deniz ; Uzun, Oguz

Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians' preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics. Patients' characteristics and disease profiles were analyzed to identify factors associated with the prescription of add-on LAMA across the entire cohort. A comparative analysis was performed among three groups: MART (ICS/formoterol as a maintenance and reliever therapy) plus LAMA, Conventional (ICS/LABA as a maintenance and short-acting beta agonist as reliever) plus LAMA and Triple (ICS/LABA/LAMA single inhaler). LAMAs were added to ICS/LABA in 11.7 % of patients in the national registry. Logistic regression analysis revealed that older age, low FEV1 (%), Asthma Control Test (ACT) scores less than 20, and severe exacerbation were the main factors influencing the initiation of LAMA in our registry. However, demographic characteristics of asthma, control status, pulmonary function test results were similar among the three groups of LAMA users (p > 0.05). Physicians used LAMAs without phenotyping based on allergic status or eosinophil levels (p > 0.05). Mepolizumab was added after LAMA in all patients, while omalizumab was initiated before LAMA in 16.9 % of the patients receiving LAMA along with biologics. Add-on LAMAs were predominantly prescribed for older, uncontrolled, and exacerbated asthma patients with low FEV1.

100 Deals associated with Medeniyet University

100 Translational Medicine associated with Medeniyet University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Jan 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Medeniyet University

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Jan 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing